Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively degenerate. However, long-term analysis of human iPS cell-derived dopaminergic neurons in primate PD models has never been performed to our knowledge. Here we show that human iPS cell-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of PD (Macaca fascicularis) treated with the neurotoxin MPTP. Score-based and video-recording analyses revealed an increase in spontaneous movement of the monkeys after transplantation. Histological studies showed that the mature dopaminergic neurons extended dense neurites into the host striatum; this effect was consistent regardless of whether the cells were derived from patients with PD or from healthy individuals. Cells sorted by the floor plate marker CORIN did not form any tumours in the brains for at least two years. Finally, magnetic resonance imaging and positron emission tomography were used to monitor the survival, expansion and function of the grafted cells as well as the immune response in the host brain. Thus, this preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Morizane et al. and Kikuchi et al. both showed that an improvement of engraftment and reduced immune reaction were observed using MHC matching of iPSC-derived dopaminergic neurons in unlesioned non-human primates [98,99].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [99]
In the citing paper
“A comprehensive study of human iPSC-derived dopamine neuron progenitor cells expressing specific markers of the neural floor plate (CORIN+; FOXA2+; TUJ1+; PAX6−) and transplanted into a monkey model of Parkinson’s disease showed stronger evidence of behavioural benefits, of cellular integration of mature dopamine neurons within the putamen, and of extension of their dense neurites into the host st”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
In the citing paper
“Most of the transplanted cells expressed FOXA2 and a third expressed tyrosine hydroxylase consistent with mature functional dopamine neurons.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Cited by
Items 401–500 of 705
Research progress of cell treatment strategy in Parkinson's disease
Peng, Y., Chen, J., Hu, H., Liu, W., Liang, W., & Wang, J. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104061 · Cited by 12
“(Kikuchi et al., 2017).”
Chemical decontamination of iPS cell-derived neural cell mixtures
Mao, D., Chung, X. K. W., Andoh-Noda, T., Qin, Y., Sato, S., Takemoto, Y., Akamatsu, W., Okano, H., & Uesugi, M. (2018) · Chemical Communications · doi:10.1039/c7cc08686e · Cited by 8
A compendious summary of Parkinson’s disease patient-derived iPSCs in the first decade
Ren, C., Wang, F., Guan, L.-N., Cheng, X.-Y., Zhang, C.-Y., Geng, D., & Liu, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.16 · Cited by 9
Xu, Y., Ding, W., Li, S., Li, C., Gao, D. Y., & Qiu, B. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02704-7 · Cited by 8
Subhramanyam, C. S., Cao, Q., Wang, C., Heng, Z. S., Zhou, Z., & Hu, Q. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02678-2 · Cited by 8
“Remarkably, the stem cell-derived dopaminergic neurons have undergone successful preclinical testing in the PD model [2, 55, 56].”
BackgroundCreating Genetically Modified Marmosets
Sasaki, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811829-0.00020-0 · Cited by 11
Furmanski, O., Nieves, M. D., & Doughty, M. L. (2019) · Journal of Visualized Experiments · doi:10.3791/59561 · Cited by 10
Fernandes, L., Santos, A. G., Sampaio, T. B., Sborgi, S. M. S., Prediger, R. D., Ferro, M., Franco, G. C. N., Lipinski, L. C., & Miyoshi, E. (2020) · Human & Experimental Toxicology · doi:10.1177/0960327120938851 · Cited by 7
“Clinically, PD is characterized by motor and nonmotor symptoms mainly caused by the loss of dopaminergic neurons in the substantia nigra pars compacta and the consequent reduction of striatal dopamine levels.(3) PD etiology is multifactorial, being associated with the combination of genetic and environmental factors.”
BackgroundAtkinson, E. A., Gregory, H. N., Carter, L. N., Evans, R. E., Roberton, V. H., Dickman, R., & Phillips, J. B. (2025) · Biomaterials Science · doi:10.1039/d4bm01566e · Cited by 8
Clinical translational research on stem cell products: prospects and challenges
Chen, S., ZHANG, L., Ren, Y., Bai, X., Wei, X., Chai, M., 崔苏甦, Zhao, X., & Deng, H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02582-y · Cited by 18
“189 Second, immunogenicity and GvHD are also major challenges faced in the clinical application of PSCs. Desgres et al. noted that allogeneic PSC transplantation may trigger immune rejection, reducing graft survival and function.”
Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases
Aishwarya, L., Dharmarajan, A., & Kannan, S. (2021) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666210810105136 · Cited by 7
Hossein‐Khannazer, N., Vosough, M., Salahi, S., Mousavi, M. A., & Azizi, G. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201100238 · Cited by 8
“They demonstrated that whether the cells were obtained from PD patients or healthy people, dopaminergic neuronal grafts generate neurites in the host striatum [144].”
Wang, M., Liu, Y., Wang, Z., Qiao, L., Ma, X., Hu, L., Kong, D., Wang, Y., & Ye, H. (2022) · Advanced Science · doi:10.1002/advs.202202858 · Cited by 7
Stem Cell-Based Approaches in Parkinson's Disease Research
Kim, M. S., Yoon, S., Choi, J., Kim, Y. J., & Lee, G. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc23169 · Cited by 9
“Factors influencing therapeutic efficacy, including viability, functional integration, and the establishment of appropriate neural circuits within the transplanted cells, are substantial and necessitate optimization to maximize clinical advantages (61, 62).”
Nakamura, Y., Niho, S., & Shimizu, Y. (2024) · Cells · doi:10.3390/cells13110893 · Cited by 9
“…differentiated cells is being explored in various diseases and applications, including age-related macular degeneration [5], Parkinson’s disease [43,44], platelet production [45,46], and heart failure [47,48]. iPSCs have also been used in reproductive medicine, and it has been reported that…”
BackgroundPurification technologies for induced pluripotent stem cell therapies
Generali, M., Fujita, Y., Kehl, D., Hirosawa, M., Emmert, M. Y., TAKAHASHI, J. C., Hoerstrup, S. P., & Saito, H. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00220-2 · Cited by 11
Self-citationLiu, J., Ji, Z., He, Q., Chen, H., Xu, X., Mei, Q., Hu, Y., & Zhang, H. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106683 · Cited by 9
“Kikuchi et al. (2017) further demonstrated that dopaminergic neurons derived from human iPSCs can survive, integrate, and restore motor deficits in macaques treated with the neurotoxin MPTP, highlighting the therapeutic potential of iPSC-derived dopaminergic neurons for PD.”
Manipulating cell fate while confronting reproducibility concerns
Osterloh, J. M., & Mullane, K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.016 · Cited by 7
Egawa, N., Suzuki, H., Takahashi, R., Hayakawa, K., Li, W., Lo, E. H., Arai, K., & Inoue, H. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20910324 · Cited by 9
Self-citationRieux, A. D. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101460 · Cited by 8
Feng, S., Zhang, T., Ke, W., Xiao, Y., Guo, Z., Lu, C., Li, S., Guo, Z., Liu, Y., Tan, G., et al. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac008 · Cited by 7
“In recent years, attempts have been made to investigate the therapeutic benefits of human iNPCs in monkeys, mainly in lesioned monkey models of PD [11, 12].”
Stabilized generation of human iPSC-derived liver organoids using a modified coating approach
Kamishibahara, Y., Okamoto, S., Ohkuma, T., & Taniguchi, H. (2022) · Biology Methods and Protocols · doi:10.1093/biomethods/bpac034 · Cited by 8
Miniature-swine iPSC-derived GABA progenitor cells function in a rat Parkinson’s disease model
Guo, Y., Zhu, H., Wang, Y., Sun, T., Xu, J., Wang, T., Guan, W., Wang, C., Liu, C., & Ma, C. (2023) · Cell and Tissue Research · doi:10.1007/s00441-022-03736-4 · Cited by 7
Yao, K., Gan, J.-M., Zhao, D. S., Li, M., Shen, X., Yang, Y., Feng, P., & Shen, Q. (2023) · Nano Research · doi:10.1007/s12274-023-5729-4 · Cited by 7
Lyu, Y., Su, Z., Ye, G., He, X., Liu, Y., Yin, Q., Xie, F., Xu, L., Chen, Y., & Long, D. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112243 · Cited by 8
Repairing the Brain: Gene Therapy
Björklund, T. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181485 · Cited by 8
Parkinson’s disease grafts benefit from well-timed growth factor
Studer, L., & Tabar, V. (2020) · Nature · doi:10.1038/d41586-020-01486-3 · Cited by 7
Induced pluripotent Stem Cells: Where we are currently?
Rančić, N., Rascanin, S., Miljković, M. N., & Jovanović, M. (2020) · Naucni casopis urgentne medicine - Halo 194 · doi:10.5937/halo26-27861 · Cited by 8
Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?
Nandakumar, S., Shahani, P., Datta, I., & Pal, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00525 · Cited by 7
Liao, Y., Liao, C., Chen, L.-R., & Yang, J. (2022) · Animal Biotechnology · doi:10.1080/10495398.2021.2020130 · Cited by 7
Creating a graft-friendly environment for stem cells in diseased brains
Tsai, R. Y. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci98490 · Cited by 7
Induced Pluripotent Stem Cells; New Tools for Investigating Molecular Mechanisms in Anorexia Nervosa
Maussion, G., Demirova, I., Gorwood, P. A. P. M., & Ramoz, N. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00118 · Cited by 10
“These two neuronal cell subtypes, derived from human IPSCs, have to be further investigated in the context of AN (beginning with their transcriptome and methylome), as procedures to generate them are now available (73, 74).”
BackgroundHijioka, M., Ikemoto, Y., Fukao, K., Inoue, T., Kobayakawa, T., Nishimura, K., Takata, K., Agata, K., & Kitamura, Y. (2021) · Neurochemical Research · doi:10.1007/s11064-020-03226-5 · Cited by 6
Developing Humanized Animal Models with Transplantable Human iPSC-Derived Cells
Ma, M., Ge, J.-Y., Nie, Y., Li, Y., & Zheng, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901034 · Cited by 7
“In a crab-eating monkey model with Parkinson’s disease (PD), induced by the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), hiPSC-derived dopaminergic progenitor cells expressed markers of dopaminergic neuron in the midbrain after transplanted in vivo [ 184].”
BackgroundPereira, M. F., Shyti, R., & Testa, G. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.05.004 · Cited by 8
Formation and Long-Term Culture of hiPSC-Derived Sensory Nerve Organoids Using Microfluidic Devices
Ogawa, T., Yamada, S., Fukushi, S., Imai, Y., Kawada, J., Ikeda, K., Ohka, S., & Kaneda, S. (2024) · Bioengineering · doi:10.3390/bioengineering11080794 · Cited by 8
“Notably, the use of human recombinant laminin fragments [25,26] as alternatives to ECM gels is a promising approach.”
BackgroundXu, J., Gong, W., Mo, C., Hou, X., & Ou, M. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10799-z · Cited by 6
Hojo, M. A., Tsuzuki, T., Ozawa, Y., Araki, T., & Sakurai, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-11108-5 · Cited by 6
“Some directed differentiation protocols from hiPSCs may even take several months for induction 5,10,16,17,20,21 , which is currently a major bottleneck for the improvement of the reproducibility and robustness of these protocols.”
InfluentialBordoni, M., Fantini, V., Pansarasa, O., & Cereda, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80055 · Cited by 6
“The authors reported an increase in spontaneous movement of the monkeys, demonstrating for the first time that such transplantation could be clinically applicable for the treatment of PD patients [45].”
BackgroundLandeck, N., Mazza, M. C., Duffy, M. F., Bishop, C., Sortwell, C. E., & Cookson, M. (2021) · Journal of Visualized Experiments · doi:10.3791/62128 · Cited by 10
Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy
Singh, S., Singh, T., Kunja, C., Dhoat, N. S., & Dhania, N. K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174568 · Cited by 7
Mourtzi, T., & Kazanis, I. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336137 · Cited by 6
“…neurons in the rat striatum (Rath et al., 2013) and of 16,000 new dopaminergic neurons in the macaque brain is sufficient for motor improvement (Kikuchi et al., 2011, 2017); while, 2–4 million grafted cells are needed to produce a range of 16,000–100,000 viable dopaminergic neurons in the…”
Neurotrophic Factors in Parkinson’s Disease: Clinical Trials
Mahato, A. K., & Saarma, M. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_4 · Cited by 7
Bray, N. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.120 · Cited by 6
Tan, T., Lin, X., Tu, K., Tang, J., Yin, S., Dai, L., Lei, P., Dong, B., Hu, H., Fan, Y., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-5183-y · Cited by 8
A novel Tungsten-based fiducial marker for multi-modal brain imaging
Ose, T., Autio, J. A., Ohno, M., Nishigori, K., Tanki, N., Igesaka, A., Mori, T., Doi, H., Wada, Y., Nakajima, I., et al. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.04.014 · Cited by 7
Self-citationEngraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair
Zygogianni, O., Kouroupi, G., Taoufik, E., & Matsas, R. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0655-1_3 · Cited by 6
A new primate model of hypophyseal dysfunction
Kawabata, T., Suga, H., Takeuchi, K., Nagata, Y., Sakakibara, M., Ushida, K., Ozone, C., Enomoto, A., Kawamoto, I., Itagaki, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90209-3 · Cited by 6
de Rham, C., Sollet, Z. C., Burkhard, P. R., & Villard, J. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0201 · Cited by 7
Yamauchi, Y., Hirata, I., Tanimoto, K., & Kato, K. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27445 · Cited by 6
“Cell transplantation therapy with NPCs attracts much attention as a new therapeutic methodology against severe intractable diseases such as spinal cord injury, Parkinson's disease, and Alzheimer's disease (Borlongan, 2012; Kameda, Imamura, & Nakashima, 2018; Kikuchi et al., 2017).”
Application of Optogenetics for Muscle Cells and Stem Cells
Asano, T., Teh, D. B. L., & Yawo, H. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-8763-4_23 · Cited by 8
Differentiation of Human Pluripotent Stem Cells Into Specific Neural Lineages
Chang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H., Chiou, T., Harn, H., Lin, S., & Ho, T. (2021) · Cell Transplantation · doi:10.1177/09636897211017829 · Cited by 8
Tiklová, K., Nolbrant, S., Fiorenzano, A., Björklund, Å. K., Sharma, Y., Heuer, A., Gillberg, L., Hoban, D. B., Cardoso, T., Adler, A. F., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/720870 · Cited by 6
Self-citationSupramolecular nanostructure mimics GDNF trophic effects in vitro on human dopaminergic neurons
Carballo-Molina, O. A., Edelbrock, A. N., Alvarez-Saavedra, M., Álvarez, Z., Fyrner, T., Perez‐Rosello, T., Syrgiannis, Z., Chin, S. M., Takata, N., Strong, M. E., et al. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00424-z · Cited by 5
“Cell replacement therapies using human dopaminergic neurons derived from hESC 6 or hiPSCs 7 have shown motor improvement in PD models butface challenges, including lowcell survival rates (2.6 – 6%).”
InfluentialiPSCs-Derived Neurons and Brain Organoids from Patients
Zhu, W., Xu, L., Li, X., Hu, H., Lou, S.-N., & Liu, Y. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_657 · Cited by 5
RETRACTED: Recent approaches in regenerative medicine in the fight against neurodegenerative disease
Esmaeili, A., Eteghadi, A., Landi, F. S., Yavari, S. F., & Taghipour, N. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148688 · Cited by 9
RetractedCurrent clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
Feng, X. G., Xia, K., Ke, Q., Deng, R., Zhuang, J., Wan, Z., Luo, P., Wang, F., Zang, Z., Sun, X., et al. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111039 · Cited by 7
Grinand, L., & Takahashi, J. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.01.002 · Cited by 5
“In the presented study, the grafted material was obtained through a protocol intended for clinical trials [4] and was previously shown to robustly survive with low proliferation [7].”
BackgroundSelf-citationKobayashi, Y., Shigyo, M., Platoshyn, O., Marsala, S., Kato, T., Takamura, N., Yoshida, K., Kishino, A., Bravo‐Hernández, M., Juhás, Š., et al. (2023) · Cell Transplantation · doi:10.1177/09636897221107009 · Cited by 6
Miranda, C. C., Fernandes, T. G., Diogo, M. M., & Cabral, J. M. S. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_117 · Cited by 8
Kusena, J., Thomas, R. J., McCall, M., & Wilson, S. L. (2019) · Regenerative Medicine · doi:10.2217/rme-2019-0076 · Cited by 6
Balancing Expectations for Success in Stem Cell-Based Clinical Trials for Parkinson’s Disease
Lindvall, O. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.09.002 · Cited by 5
The future is now: cutting edge science and understanding toxicology
Um, J., Jung, D., & Williams, D. R. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-018-9421-5 · Cited by 5
“Cell reprogramming and the therapeutic applications of induced pluripotent stem cells (iPSCs) remain a cutting edge research area (Normile 2017; Choi et al. 2017; Kikuchi et al. 2017).”
BackgroundDetecting and Quantitating Low Fraction DNA Variants with Low-Depth SequencingPreprint
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.061747 · Cited by 5
“experiments to understand cell and organism function as well as to establish feasibility for potential therapeutics [32– 34].”
BackgroundKim, T. W., Piao, J., Bocchi, V. D., Koo, S. Y., Choi, S. J., Chaudhry, F. F., Yang, D., Cho, H., Hergenreder, E., Perera, L. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.06.631400 · Cited by 5
Ballion, B., Bonnet, M., Brot, S., & Gaillard, A. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04344-z · Cited by 6
“This finding is consistent with numerous in vitro studies using mDA neurons derived from various hiPSC lines, and reporting similar frequency ranges [19–21].”
Traumatic brain injury and neurodegenerative diseases: the role of axonal injury and amyloid-β
Bi, D., Gao, B., Shen, Y., Dai, Z., Yang, S., & Wang, L. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149873 · Cited by 6
Goyal, S., Seth, B., & Chaturvedi, R. K. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211115154450 · Cited by 5
Kuwata, F., Ohnishi, H., Yamamoto, N., Takezawa, T., Yamashita, M., Okuyama, H., Hayashi, Y., Yoshimatsu, M., Kitada, Y., Tada, T., et al. (2021) · Tissue Engineering Part A · doi:10.1089/ten.tea.2021.0071 · Cited by 4
Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?
Nasrolahi, A., Shabani, Z., Sadigh‐Eteghad, S., Salehi‐Pourmehr, H., & Mahmoudi, J. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230222144116 · Cited by 6
Advancements in Autologous Stem Cell Transplantation for Parkinson’s Disease
Shi, J., & Zhang, K.-Z. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x19666230907112413 · Cited by 5
Zhao, F., Li, C., Zhuang, Y., Yan, Y., Gao, Y., & Behnisch, T. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1288991 · Cited by 4
“PD involves the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), leading to motor deficits and potentially non-motor disorders like mild cognitive impairment (MCI) and dementia (Kikuchi et al., 2017; Hendrickx et al., 2021).”
Shah, S., Tereda, A., & Mansour, H. M. (2024) · Current Genetic Medicine Reports · doi:10.1007/s40142-024-00210-1 · Cited by 6
“The dopaminergic neurons in the substantia nigra of the midbrain, which are damaged in Parkinson's disease, account for a relatively tiny proportion of the total amount of neurons in the brain [124].”
Kayama, T., Okamoto, K., Gao, M., Ikegaya, Y., & Sasaki, T. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001178 · Cited by 4
Evidence that Neuromuscular Fatigue Is not a Dogma in Patients with Parkinson’s Disease
MARTIGNON, C., Laginestra, F. G., Giuriato, G., Pedrinolla, A., BARBI, C., VICO, I. A. D., TINAZZI, M., Schena, F. F., & Venturelli, M. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002791 · Cited by 5
“Interestingly, and in line with these results, a recent monkey study succeeded in reestablishing dopamine concentrations and improved all PD signs by implanting dopaminergic neuronal grafts, supporting the evidence of the key role of the central motor drive (31).”
ResultWilson, H., de Natale, E. R., & Politis, M. (2022) · Stem Cells · doi:10.1093/stmcls/sxac039 · Cited by 5
Chen, Y., Yin, Q., Cheng, X.-Y., Zhang, J., Jin, H., Li, K., Mao, C., Wang, F., Bei, H.-Z., & Liu, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.947927 · Cited by 5
“Neurotoxins such as MPP+ (Emborg et al., 2013; Kikuchi et al., 2017) and genetic mutations in PARK genes, such as LRRK2 (West et al., 2005), have become major components of the origin of PD. Leucine-rich repeat kinase 2 (LRRK2) is involved in inflammation (Wallings and Tansey, 2019; Cabezudo et…”
BackgroundXu, J., Li, Y., Zhu, H., Wu, W., Liu, Y., Guo, Y., Guan, W., Liu, C., & Ma, C. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5196 · Cited by 4
Potential Plausible Role of Stem Cell for Treating Depressive Disorder: a Retrospective Review
Chang, Z., Wang, Q., Li, L.-H., Jiang, B., Zhou, X., Zhu, H., Sun, Y., Pan, X., Tu, X.-X., Wang, W., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03843-5 · Cited by 4
Development of Neural Stem Cell-Based Therapies for Parkinson’s Disease
Lee, J., Tsai, C., & Chou, C.-H. (2018) · InTech eBooks · doi:10.5772/intechopen.73870 · Cited by 4
“It was demonstrated that human iPSC-derived DA progenitor cells survived and functioned as midbrain DA neurons in a primate model of PD (Macacafascicularis) treated with the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [84].”
BackgroundRegenerative medicine for urological tissues: Updated review 2018
Kanematsu, A. (2018) · International Journal of Urology · doi:10.1111/iju.13762 · Cited by 4
Roles of microRNAs in Parkinson’s and other neurodegenerative diseases
Lai, Q., Murgia, N., Parkkinen, I., Domanskyi, A., & Vinnikov, I. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815669-8.00008-7 · Cited by 4
Zheng, W., & Chen, Z. (2019) · Journal of Visualized Experiments · doi:10.3791/59690 · Cited by 4
A roadmap for neurodevelopmental disease modeling for non-stem cell biologists
Ernst, C. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0344 · Cited by 4
Gopurappilly, R. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_643 · Cited by 5
Microfluidic chip for label-free removal of teratoma-forming cells from therapeutic human stem cells
Wellmerling, K., Lehmann, C., Singh, A. K., & Kirby, B. J. (2020) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2020.100030 · Cited by 4
“Of tissue derived from hiPSCs, neural stem and progenitor cells are a promising therapy for treating chronic neurodegenerative diseases, for example Alzheimer’s disease[11] and Parkinson’s disease[12, 13].”
BackgroundReprogrammed cells relieve Parkinson's symptoms in trials
Callaway, E. (2017) · Nature · doi:10.1038/nature.2017.22531 · Cited by 4
Филиппова, А., Bonini, F., Efremova, L. V., Preynat‐Seauve, O., Béduer, A., Krause, K., & Braschler, T. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.30.927244 · Cited by 4
Doi, D., Kikuchi, T., Morizane, A., & Takahashi, J. B. (2020) · doi:10.21203/rs.3.pex-954/v1 · Cited by 4
Self-citationKim, T. W. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01394 · Cited by 4
“…potential of hPSC-based therapies in PD, recent reports indicate that cell replacement therapy using hPSC-derived DA cells has progressed from the preclinical phase to actual clinical trials in PD patients (Kikuchi et al., 2017; Schweitzer et al., 2020; Kim et al., 2021; Kirkeby et al., 2023).”
Zhang, F., Gao, K., Zhang, J., Li, S., Li, Y., Wang, J., Wu, Y., Jiang, Y., & Wu, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04888-4 · Cited by 4
“The enhancement of dopaminergic neurons may be beneficial for neurodegenerative diseases, such as Parkinson’s [36], where restoring specific neuronal populations is critical.”
Bézard, E., Anderson, R. M., Badin, R. A., Bergman, H., Boehringer, A. V., Borgognon, S., Emborg, M. E., Kordower, J. H., Li, J., Martel, A., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01088-8 · Cited by 8
Self-citationMendonça, L. S., Henriques, D., Fernandes, V., Moreira, R., Brás, J., Duarte, S., Schwamborn, J. C., & de Almeida, L. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-53542-x · Cited by 3
“DLK1, EN2, and GBX2 genes have been previously studied as potential predictive markers of cell survival and differentiation after brain transplantation 51 .”
BackgroundWang, Y., Wang, Z., Wang, L., Sun, Y., Song, H., Cheng, X., He, X., Gao, Z., & Sun, Y. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70027 · Cited by 4
“Whether the donor cells are from normal individuals or PD patients, there is no difference in the survival and activities of DA neurons in cynomolgus monkeys (Kikuchi et al. 2017).”
Autologous cells, no longer lost in translation
Parmar, M., & Falk, A. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.02.004 · Cited by 3
Self-citationFunctional carbon-based nanomaterials for engineered tissues toward organ regeneration
Jodat, Y. A., & Shin, S. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102906-0.00021-0 · Cited by 3
Katolikova, N. V., Malashicheva, A., & Gainetdinov, R. R. (2020) · Molecular Biology · doi:10.31857/s0026898420060063 · Cited by 5
Krog, R. T., de Miranda, N. F. C. C., Vahrmeijer, A. L., & Kooreman, N. G. (2021) · Cancers · doi:10.3390/cancers13225789 · Cited by 3
Katolikova, N. V., Malashicheva, A., & Gainetdinov, R. R. (2020) · Molecular Biology · doi:10.1134/s0026893320060060 · Cited by 3
Metadata
- Authors
- Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., Morita, S., Yamamoto, M., Okita, K., Nakagawa, M., Parmar, M., & Takahashi, J.
- Affiliations
- Kyoto University (JP)
- RIKEN (JP)
- Lund University (SE)
- Corresponding author
- Takahashi, Jun
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7669
- Pages
- 592-596
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2751466955
- Cited by
- 702
- References
- 48
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 74 · 2023: 69 · 2022: 91 · 2021: 89 · 2020: 123 · 2019: 88 · 2018: 75 · 2017: 6
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15H02502, 15H02540, 16H03306, 15K12779, 16H03300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, dopaminergic neurons, induced pluripotent stem cells, cell transplantation, nonhuman primate model, Macaca fascicularis, MPTP-induced neurotoxicity, midbrain dopaminergic neurons, spontaneous movement, neurite outgrowth, corin, tumor formation, cell survival, cell tracking, immune response, cell therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Survival, Disease Models, Animal, Humans, Macaca fascicularis, Magnetic Resonance Imaging, Male, Mesencephalon, Movement, Parkinson Disease, Serine Endopeptidases, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurites, Neostriatum, Regenerative Medicine, Cell Proliferation, Positron-Emission Tomography, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.